Radiation-induced activation of the STING/type I IFN pathway enhances tumor-suppressive inflammation by recruiting myeloid cells through the CCR2 pathway, and treatments targeting CCR2 have mitigated the immunosuppressive effects of radiotherapy and STING agonist strategies [7]. Here, CCR2 is linked to neoplasm.